Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 14/20 | 0.38 |
| ▸ | PDE6D | O43924 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833713 | 0.95 | NPY1R (0.39) | ACP1PDE6DNPY1RTLR7HTR4 | |
| SCHEMBL6840074 | 0.94 | ACP1 (0.44) | ACP1NPY1R | |
| SCHEMBL6838577 | 0.90 | PDE6D (0.37) | ACP1PDE6DNPY1RTLR7HTR4 | |
| SCHEMBL6833751 | 0.90 | ACP1 (0.38) | ACP1PDE6DNPY1RTLR7HTR4 | |
| SCHEMBL6840049 | 0.90 | ALDH1A1 (0.38) | ACP1PDE6DNPY1RHTR4MERTK | |
| SCHEMBL6838696 | 0.89 | NPY1R (0.40) | ACP1PDE6DNPY1RTLR7HTR4 | |
| SCHEMBL6840122 | 0.89 | NPY1R (0.36) | ACP1PDE6DNPY1RTLR7HTR4 | |
| SCHEMBL7493132 | 0.87 | ACP1 (0.38) | ACP1PDE6DNPY1RMERTK | |
| SCHEMBL6838389 | 0.86 | ACP1 (0.46) | ACP1PDE6DNPY1RHTR4 | |
| SCHEMBL6833817 | 0.86 | KHK (0.38) | PDE6DNPY1RHTR4MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | ACP1 490/4885PDE6D 2316/4885NPY1R 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.